Caffeine and progression of parkinson disease

David K. Simon, Christopher J. Swearingen, Robert A. Hauser, Joel M. Trugman, Michael J. Aminoff, Carlos Singer, Daniel Truong, Barbara C. Tilley

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

Objective: Caffeine use is negatively associated with the risk of developing Parkinson disease (PD) and is protective in animal models of PD, but the relationship between caffeine intake and rate of progression of PD is unknown. We assessed this relationship using data from 2 recent clinical trials of PD. Methods: Data were ascertained from 2 recent 1-year clinical trials that together included 413 early PD subjects who did not require symptomatic therapy at the time of study entry. Exploratory analyses compared caffeine intake with rate of progression of PD, as measured by either the likelihood of progression to the point of requiring symptomatic therapy or by change in the total Unified Parkinson Disease Rating Scale score. Results: Rate of progression of PD did not differ significantly between those in the highest and lowest quartiles for caffeine use for either of the primary measures or for secondary analyses of changes in scores on the motor or activities of daily living subsections of the Unified Parkinson Disease Rating Scale. Other secondary analyses yielded variable results. Conclusions: These data do not reveal a consistent relationship between caffeine intake and rate of progression of PD by these measures, although a larger study is required for sufficient power to more fully assess this relationship.

Original languageEnglish (US)
Pages (from-to)189-196
Number of pages8
JournalClinical neuropharmacology
Volume31
Issue number4
DOIs
StatePublished - Jul 2008
Externally publishedYes

Keywords

  • Adenosine A2A receptor
  • Coffee
  • Disease modifying
  • Neuroprotection

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Caffeine and progression of parkinson disease'. Together they form a unique fingerprint.

  • Cite this

    Simon, D. K., Swearingen, C. J., Hauser, R. A., Trugman, J. M., Aminoff, M. J., Singer, C., Truong, D., & Tilley, B. C. (2008). Caffeine and progression of parkinson disease. Clinical neuropharmacology, 31(4), 189-196. https://doi.org/10.1097/WNF.0b013e31815a3f03